Regentis Biomaterials Raises $15MM for U.S. Pivotal Clinical Trial

Regentis Biomaterials closed a US $15MM Series D investment round. Funds will primarily support a pivotal U.S. clinical trial of GelrinC® hydrogel, a cell-free implant for the treatment of articular knee cartilage injuries.

The round was led by Haisco Pharmaceutical Group in China, which will serve as exclusive distributor for GelrinC in that...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us